Results 241 to 250 of about 124,738 (260)

HIV Nucleoside Reverse Transcriptase Inhibitors

2007
openaire   +1 more source

Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors

International Journal of Biochemistry and Cell Biology, 2004
Robert A Domaoal, Lisa M Demeter
exaly  

A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial

Lancet, The, 2006
Grace Peng, Katherine Huppler Hullsiek, Mary van den Berg-Wolf   +2 more
exaly  

Tetrazole thioacetanilides: Potent non-nucleoside inhibitors of WT HIV reverse transcriptase and its K103N mutant

Bioorganic and Medicinal Chemistry Letters, 2006
Ralph Laufer, Vandna Munshi, Vincenzo Summa   +2 more
exaly  

Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2011 – 2014)

Expert Opinion on Therapeutic Patents, 2014
Lingzi Zhang, Yu'Ning Song, Peng Zhan
exaly  

Discovery of dimeric inhibitors by extension into the entrance channel of HIV-1 reverse transcriptase

Bioorganic and Medicinal Chemistry Letters, 2012
Mariela Bollini, Robert A Domaoal, Krasimir A Spasov   +2 more
exaly  

Higher Rates of Viral Suppression with Nonnucleoside Reverse Transcriptase Inhibitors Compared to Single Protease Inhibitors Are Not Explained by Better Adherence

HIV Clinical Trials, 2004
David Guzman, Elise D Riley
exaly  

Lead Optimization of Diarylpyrimidines as Non‐nucleoside Inhibitors of HIV‐1 Reverse Transcriptase

ChemMedChem, 2010
Fen-Er Chen, Christophe Pannecouque, Jan Balzarini   +2 more
exaly  

Nucleotide reverse transcriptase inhibitors

Reactions Weekly, 2015
openaire   +1 more source

Benzophenones as inhibitors of reverse transcriptase

Expert Opinion on Therapeutic Patents, 2001
openaire   +1 more source